Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade < 1 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study)
Failure to recover from all adverse events/toxicities related to prior anticancer therapies to grade 1 per National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03; NOTE: Exception: patients with any grade of alopecia are allowed to enter the study
Participants who have had chemotherapy within 14 days prior registration or those who have not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade =< 1 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study); there is no washout period required for trastuzumab or for endocrine therapy; however subjects who received fulvestrant immediately prior to this trial should wait at least 28 days before receiving their first dose of fulvestrant on study
Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI)-CTCAE version 4.03 grade < 1 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study)
Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 to less than or equal to grade 1 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study)
Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 grade =< 1 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study)
Must have received prior therapy with a MET inhibitor; patients must have recovered from all toxicities related to prior anticancer therapies to grade =< 1 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.0); patients with any grade of alopecia are allowed to enter the study
Patients who have received prior chemotherapy, other ALK inhibitors, biologic therapy, or other investigational agents, must have recovered from all toxicities related to prior anticancer therapies to grade ?1 (CTCAE v 4.03). Patients with grade ? 2 peripheral neuropathy or any grade of alopecia, fatigue, nail changes or skin changes are allowed to enter the study
Patients may have received prior chemotherapy, crizotinib (other ALK inhibitors are not allowed), biologic therapy or other investigational agents. Patients must have recovered from all toxicities related to prior anticancer therapies to grade ? 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.
Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade =< 1 (Exception to this criterion: patients with any grade of alopecia are allowed to enter the study)
Patients must have recovered from all clinically relevant toxicities related to prior anticancer therapies to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03); exception to this criterion: patients with any grade of alopecia are allowed to enter the treatment
Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade < 1 (exception to this criterion: patients with any degree of alopecia are allowed to enter the study)
Patients must have recovered from all toxicities related to any prior anticancer therapies to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), provided that any concomitant medication is given prior to initiation of treatment with ceritinib; exception to this criterion: patients with any grade of alopecia are allowed to enter the treatment
Patients must have recovered from all toxicities related to prior anticancer therapies to grade ? 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.
Patients must have recovered from all toxicities related to prior anticancer therapies to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), provided that any concomitant medication is given prior to initiation of treatment with ceritinib; exception to this criterion: patients with any grade of alopecia are allowed to enter the treatment
Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade < 1 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study)
Patient has not recovered from all toxicities related to prior anticancer therapies to grade 1 per National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study)
Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade < 3 (exception to this criterion: patients with any grade of alopecia or neuropathy are allowed to enter the study)
Patient has not recovered from all toxicities related to prior anticancer therapies to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade =< 1 (exception to this criterion: patients with any grade of alopecia are allowed to enter the study).
Patients must have recovered from all toxicities related to prior anticancer therapies to grade =< 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03) provided that concomitant medication is given prior to initiation of treatment with LDK378 [ceritinib], except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study; additionally, patients with any grade of alopecia are allowed on treatment
Patients must have recovered from all toxicities related to prior anticancer therapies to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03); exception to this criterion: patients with any grade of alopecia are allowed to enter the treatment
Patients who have received prior chemotherapy, other ALK inhibitors, biologic therapy, or other investigational agents, must have recovered from all toxicities related to prior anticancer therapies to grade ? 1 (CTCAE v 4.03) prior to starting study drug. Patients with grade ? 2 peripheral neuropathy or any grade of alopecia, nail changes or skin changes are allowed to enter the study.
